1
Clinical Trials associated with MAGE-A1, Her-2/neu, FBP Peptides Ovarian Cancer Vaccine(University of Virginia)Evaluation of the Immunogenicity of Vaccination With Synthetic Peptides in Adjuvant in Patients With Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving vaccine therapy and chemotherapy after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase II trial is studying how well giving vaccine therapy together with paclitaxel and carboplatin works in treating patients who are undergoing surgery for stage III or stage IV ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
100 Clinical Results associated with MAGE-A1, Her-2/neu, FBP Peptides Ovarian Cancer Vaccine(University of Virginia)
100 Translational Medicine associated with MAGE-A1, Her-2/neu, FBP Peptides Ovarian Cancer Vaccine(University of Virginia)
100 Patents (Medical) associated with MAGE-A1, Her-2/neu, FBP Peptides Ovarian Cancer Vaccine(University of Virginia)
100 Deals associated with MAGE-A1, Her-2/neu, FBP Peptides Ovarian Cancer Vaccine(University of Virginia)